SecBot SecBot
6-K ·Filed Jun 22, 2026

RDY

DR REDDYS LABORATORIES LTD
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago SEC0001575872-26-000428
Notable filing: 6-K
Actionable Insight • Neutral

Routine ESOP exercise disclosure, no trading signal. Monitor next 20-F or earnings release for fundamental updates on revenue, margins, and regulatory pipeline.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$13.91
T+0 close · Jun 22, 2026 · via day close
Latest settled
−9.42%
T+20 · $12.60
Vs SPY
−9.27%
α at T+20
Next horizon
T+60
due 2mo ago
  1. T+0 · Jun 22 $13.91entry
  2. T+1 · 5mo ago +2.88%α +4.33% · $14.31
  3. T+5 · 5mo ago +6.83%α +7.29% · $14.86
  4. T+20 · 4mo ago −9.42%α −9.27% · $12.60
  5. T+60 · due 2mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dr. Reddy's filed a routine 6-K disclosing a small equity allotment of 6,730 shares upon exercise of employee stock options under existing ESOP schemes. This is a standard administrative disclosure with no new material financial, operational, or regulatory information.

Key Facts

  • Allotted 6,730 equity shares of Re.1 each on June 19, 2026 to eligible employees exercising stock options under Dr. Reddy's Employees Stock Option Scheme, 2002 and Dr. Reddy's Employees ADR Stock Option Scheme, 2007.
  • Exercise prices were Re.1 (2,455 shares), Rs.562.80 (2,000 shares), and Rs.735.80 (2,275 shares) per share.
  • Total issued shares post-allotment: 83,46,76,800 equity shares of Re.1 each, representing a negligible 0.008% increase from prior outstanding.
  • No lock-in restrictions; shares rank pari passu with existing equity.

Financial Impact

Minimal dilution of approximately 0.008% of outstanding shares; aggregate proceeds from exercises are immaterial relative to the company's $11.7B market cap.

dilution

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
52% bullish (44 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000428
Document: 0001575872-26-000428-index.html0001575872-26-000428
Document: 0001575872-26-000428.txt0001575872-26-000428

Track record

73 reports on RDY

Performance horizon

7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 12 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
  2. Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
  3. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
  4. Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
  5. Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
  6. Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
  7. Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  8. Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  9. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
  10. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
Showing 10 of 73

US Market Status

Market Closed · Opens in 5h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026